Pfizer Inc. (NYSE:PFE) Shares Purchased by Sunbelt Securities Inc.

by · The Cerbat Gem

Sunbelt Securities Inc. raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 19.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 71,237 shares of the biopharmaceutical company’s stock after purchasing an additional 11,391 shares during the quarter. Sunbelt Securities Inc.’s holdings in Pfizer were worth $1,882,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. increased its holdings in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton increased its holdings in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. raised its position in Pfizer by 1.5% during the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after acquiring an additional 401 shares in the last quarter. Finally, Providence Capital Advisors LLC lifted its stake in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after acquiring an additional 409 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.1%

Pfizer stock opened at $23.02 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $130.88 billion, a PE ratio of 16.33, a PEG ratio of 0.64 and a beta of 0.58. The business’s 50-day simple moving average is $23.44 and its 200-day simple moving average is $25.22.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business posted $0.82 EPS. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.47%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

Several analysts have commented on PFE shares. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Check Out Our Latest Stock Report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).